Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €31.42 EUR
Change Today +0.32 / 1.03%
Volume 0.0
ZA7 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:08 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

175 Portland Street

4th Floor

Boston, MA 02114

United States

Phone: 617-622-4003

Fax:

Zafgen, Inc., a biopharmaceutical company, focuses on advancing novel therapeutics for patients suffering from severe obesity and obesity-related disorders. Product Pipeline Beloranib Beloranib, the company’s major product candidate, is a novel, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity; and severe obesity in the general population. In 2014, the company completed a Phase 2a clinical trial evaluating beloranib’s ability to reduce body weight and to improve hyperphagia in patients with PWS. The company completed a Phase 2 clinical trial of beloranib administered twice weekly in 14 patients with HIAO caused by the treatment of craniopharyngioma or pituitary macroadenoma. The company is pursuing clinical development of beloranib as a treatment for severely obese patients in the general population, including patients otherwise eligible for bariatric surgery. The company initiated a Phase 2b clinical trial of beloranib as a treatment for severe obesity in the general population in patients who also have type 2 diabetes in 2014. The company is also evaluating additional proprietary methionine aminopeptidase 2 (MetAP2) inhibitors beyond beloranib as potential development candidates that would provide increased patient convenience in the form of oral dosing, or an otherwise improved clinical profile. The company initiated its Phase 3 clinical program, which is planned to consist of two Phase 3 clinical trials of beloranib in patients with PWS, with the first Phase 3 trial in the United States having started in 2014. The company plans to initiate its second Phase 3 clinical trial of beloranib in patients with PWS in the European Union in the middle of 2015. Beloranib received orphan designation for the treatment of PWS by both the U.S. Food and Drug Administration (FDA) and the European Commission in 2013 and 2014, respectively. ZGN-839 The company has a second program focused on the delivery of MetAP2 inhibitors with targeted tissue distribution that shows early promise in animal models of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and abdominal obesity. The company’s major MetAP2 inhibitor in this class of molecules is called ZGN-839. The company plans to advance multiple candidate drugs into early development to establish clinical proof of concept, safety and tolerability of these molecules as a way to leverage its internal know-how in metabolic diseases and the effects of MetAP2 inhibitors. These compounds, typified by ZGN-839, could provide additional short-term value to the company through focused development partnerships and collaborations. Licenses The company has a license agreement with Chong Kun Dang Pharmaceutical Corp. of South Korea (CKD), pursuant to which the company licensed beloranib from CKD on a worldwide basis, with the exception of South Korea. The company has a license agreement with Children’s Medical Center Corporation (Children’s), pursuant to which the company licensed certain patent rights from Children’s on a worldwide basis. The licensed patent rights relate to decreasing the growth of fat tissue, and thereby cover the use of beloranib and related molecules as anti-obesity agents. Strategy Key elements of the company’s strategy include advancing the clinical development of beloranib in subpopulations of obese patients, including those with rare conditions, where obesity is a co-morbidity of an underlying condition; advancing the clinical development of MetAP2 inhibitors for the treatment of severely obese patients in the general population, including those who are candidates for bariatric surgery; leveraging the knowledge of its experienced team of drug developers that have deep expertise in the field of obesity, the function of MetAP2 inhibitors and metabolic diseases; maintaining flexibility in commercializing and improving the value of its development programs; and the development of other potential product cand

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZA7:GR €31.42 EUR +0.32

ZA7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZA7.
View Industry Companies
 

Industry Analysis

ZA7

Industry Average

Valuation ZA7 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZAFGEN INC, please visit www.zafgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.